Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Auris Medical (EARS)

Auris Medical (EARS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,968
  • Shares Outstanding, K 1,875
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,750 K
  • 60-Month Beta -0.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.33

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.56 +1.95%
on 07/19/19
3.20 -18.41%
on 06/27/19
-0.16 (-5.78%)
since 06/19/19
3-Month
2.41 +8.30%
on 06/04/19
6.60 -60.44%
on 04/25/19
-3.65 (-58.28%)
since 04/18/19
52-Week
2.41 +8.30%
on 06/04/19
39.40 -93.38%
on 10/15/18
-2.91 (-52.72%)
since 07/19/18

Most Recent Stories

More News
Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 2.64 (-0.38%)
Auris Medical Announces Closing of Public Offering of Common Shares

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 2.64 (-0.38%)
Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 2.64 (-0.38%)
Auris Medical Holding Ltd.:

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 2.64 (-0.38%)
Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 2.64 (-0.38%)
Auris Medical Announces Reverse Stock Split

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 2.64 (-0.38%)
Research Report Identifies National General, Eidos Therapeutics, Auris Medical Holding AG, and Realogy with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of National General Holdings Corp...

NGHC : 22.46 (+0.54%)
EIDX : 35.12 (-3.33%)
RLGY : 5.20 (-3.17%)
EARS : 2.64 (-0.38%)
Auris Medical Provides Update on Tinnitus Drug Development Strategy

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders,...

EARS : 2.64 (-0.38%)
Auris Medical Receives Positive Nasdaq Listing Determination

EQNX::TICKER_START (NasdaqGM:EARS), EQNX::TICKER_END

EARS : 2.64 (-0.38%)
Auris Medical Announces 20-F Filing

March 14, 2019 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system...

EARS : 2.64 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade EARS with:

Business Summary

Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear...

See More

Key Turning Points

2nd Resistance Point 2.70
1st Resistance Point 2.68
Last Price 2.64
1st Support Level 2.60
2nd Support Level 2.54

See More

52-Week High 39.40
Fibonacci 61.8% 25.27
Fibonacci 50% 20.91
Fibonacci 38.2% 16.54
Last Price 2.64
52-Week Low 2.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar